Financial Data and Key Metrics Changes - The company reported consolidated revenue of $126.5 million for Q1 2023, an increase of $12.6 million or 11% compared to the prior year quarter [26] - Adjusted EBITDA for the quarter was $7.9 million, reflecting an increase of $1.8 million or 28.8% over the prior year quarter [26] - GAAP diluted earnings per share increased by 50% to $0.06, while non-GAAP diluted earnings per share rose by 18.2% to $0.13 [52] Business Line Data and Key Metrics Changes - Home health and hospice revenue for the quarter was $91.1 million, up $10.6 million or 13.2% year-over-year, with adjusted EBITDA of $13.2 million, a 3.7% increase [39] - Senior living segment revenue improved to $34.6 million, an increase of $4.5 million or 15% over the prior year quarter, with adjusted EBITDA rising to $2.3 million, a 45.6% increase [46] Market Data and Key Metrics Changes - Home health admissions increased by 7.1% and Medicare home health admissions rose by 6.8% compared to the prior year quarter [40] - Same-store senior living occupancy reached 79.1%, a 370 basis point improvement year-over-year [47] Company Strategy and Development Direction - The company is focused on five key organizational priorities: leadership development, margin improvement, turnover reduction, growth, and clinical excellence [27] - A commitment to develop 100 local CEOs is underway, with seven local CEOs appointed year-to-date [28] - The company aims to optimize operations and increase margins through careful measurement of utilization and staff productivity [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2023 earnings commitments despite ongoing inflationary pressures and labor challenges [25] - The company anticipates continued growth in home health and hospice segments throughout 2023, driven by strong clinical outcomes and community engagement [42] Other Important Information - The company has made significant progress in reducing employee turnover, achieving double-digit year-over-year improvements, particularly in the senior living business [32] - The company completed one license acquisition in Q1 2023, expanding its continuum of care in Prescott, Arizona [50] Q&A Session Summary Question: What are the company's views on the Medicaid services proposal and its exposure to home care services? - Management indicated a modest exposure to home care, which is a growing segment but represents a small portion of overall home health revenue [61][62]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-Q 1675 East Riverside Drive, Suite 150, Eagle, ID 83616 (Address of Principal Executive Offices and Zip Code) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 00 ...

Financial Data and Key Metrics Changes - For the full year 2022, the company reported revenue of $473.2 million, an increase of $33.5 million or 7.6% over the prior year, and adjusted EBITDA improved by $5.1 million or 19.5% [4][24] - In Q4 2022, revenue increased by $12.9 million to $124.7 million, with adjusted EBITDA improving by $4.9 million or 98.3% over the prior year [4][24] - The company provided guidance for 2023, anticipating revenue between $503.5 million and $518.4 million, and adjusted EBITDA of $38.4 million to $42.6 million [25][41] Business Line Data and Key Metrics Changes - The home health and hospice segment saw admissions grow by 6.4% for the full year and 2.4% in Q4, with average daily census growing 5.2% year-over-year [16][44] - The senior living segment's same-store revenue improved to $126.8 million, an increase of $12.8 million or 11.2% over the prior year, with occupancy reaching 78.6%, a 330 basis-point improvement [18][19] - Adjusted EBITDA for the senior living segment improved to $6 million, up 282% over the prior year [48] Market Data and Key Metrics Changes - The company reported strong performance in historically strong markets like Arizona and Texas, despite challenges, and expects these markets to rebound [17][64] - The average monthly revenue per occupied room rose to $3,670, an increase of $282 or 8.3% year-over-year [19] Company Strategy and Development Direction - The company is focused on enhancing leadership development, aiming to triple the number of CEOs within three years [12] - There is a robust pipeline of acquisition opportunities in home health, hospice, and senior living, with a disciplined approach to executing growth strategies [21] - The company emphasizes improving clinical outcomes, operating margins, and employee experience as key areas for growth [5][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth momentum from Q4 2022 carrying into 2023, despite some expected challenges in Q1 [30][60] - The company anticipates a ramp-up in performance in the second half of 2023, with a focus on leadership development and operational efficiencies [26][41] - Management acknowledged the impact of inflation and labor costs but remains confident in the potential for margin improvement [13][72] Other Important Information - The company reported a net debt to adjusted EBITDA ratio of 1.93 times and cash flows from operations of $9 million for the year [54] - The company is committed to creating a life-changing employee experience to address elevated turnover levels and staffing shortages [20][50] Q&A Session Summary Question: What is the outlook for revenue growth and margin improvement in 2023? - Management anticipates stable but solid growth in revenue and incremental margin improvement, with conservative estimates built into the guidance [60][80] Question: Can you discuss the hospice side and the normalization of length of stay? - Management noted a 10% increase in length of stay and expects continued normalization, particularly in key markets like Arizona and Texas [63][64] Question: What are the expectations for rate increases and occupancy trends in senior living? - The company expects a 10% increase in top-line growth for senior living, with 2% to 3% from rate increases and 7% to 8% from occupancy growth [69] Question: How is the company addressing cash flow and capital expenditures? - Management expects capital expenditures to decrease to $8 million to $10 million in 2023, with improved operating cash flow anticipated due to the absence of one-time expenditures [70][71] Question: What is the strategy for margin expansion across segments? - Management indicated that margin expansion is expected across all segments, with a focus on operational efficiencies and reducing employee turnover [72][73]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-38900 _____ ...

The Pennant Group, Inc. (NASDAQ:PNTG) Q3 2022 Results Conference Call November 8, 2022 12:00 PM ET Company Participants Derek Bunker - Chief Investment Officer Brent Guerisoli - CEO John Gochnour - President Jen Freeman - CFO Conference Call Participants Tao Qiu - Stifel Scott Fidel - Stephens Operator Good day, and thank you for standing by. Welcome to The Pennant Group Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Derek Bunker. Please go ahead ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-38900 __________________________ THE PENNANT GROUP, INC. (Exact Name of Registrant as Specified in Its ...

The Pennant Group, Inc. (NASDAQ:PNTG) Q2 2022 Results Conference Call August 9, 2022 12:00 PM ET Company Participants Derek Bunker - Chief Investment Officer Brent Guerisoli - Chief Executive Officer John Gochnour - President Jen Freeman - Chief Financial Officer Conference Call Participants Jordan Bernstein - Stephens Inc Tao Qiu - Stifel Ben Hendrix - RBC Capital Markets Operator Thank you for standing by, and welcome to the Pennant Group Second Quarter 2022 Earnings Call. All lines have been placed on mu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 001-38900 __________________________ THE PENNANT GROUP, INC. (Exact Name of Registrant as Specified in Its Char ...

The Pennant Group, Inc. (NASDAQ:PNTG) Q1 2022 Results Conference Call May 10, 2022 12:00 PM ET Company Participants Derek Bunker - Chief Investment Officer Danny Walker - Chief Executive Officer Brent Guerisoli - President Jen Freeman - Chief Financial Officer John Gochnour - Chief Operating Officer Conference Call Participants Ben Hendrix - RBC Capital Markets Jordan Bernstein - Stephens Inc Operator Good day, and thank you for standing by. Welcome to The Pennant Group First Quarter 2022 Earnings Conferenc ...

Part I. Financial Information [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) Presents unaudited condensed consolidated financial statements for Q1 2022 vs Q1 2021, including balance sheets, income statements, cash flows, and notes Condensed Consolidated Balance Sheet Highlights | Account | March 31, 2022 ($ thousands) | December 31, 2021 ($ thousands) | | :--- | :--- | :--- | | **Total Current Assets** | $81,512 | $75,841 | | **Total Assets** | $507,436 | $530,297 | | **Total Current Liabilities** | $68,605 | $71,635 | | **Total Liabilities** | $389,504 | $416,053 | | **Total Equity** | $117,932 | $114,244 | Condensed Consolidated Statements of Income | Metric | Three Months Ended March 31, 2022 ($ thousands) | Three Months Ended March 31, 2021 ($ thousands) | | :--- | :--- | :--- | | **Revenue** | $113,910 | $105,663 | | **Income from operations** | $2,326 | $1,613 | | **Net income** | $1,158 | $913 | | **Diluted EPS** | $0.03 | $0.03 | Condensed Consolidated Statements of Cash Flows | Cash Flow Activity | Three Months Ended March 31, 2022 ($ thousands) | Three Months Ended March 31, 2021 ($ thousands) | | :--- | :--- | :--- | | **Net cash used in operating activities** | $(4,071) | $(7,267) | | **Net cash used in investing activities** | $(2,582) | $(3,995) | | **Net cash provided by financing activities** | $5,090 | $16,824 | | **Net (decrease) increase in cash** | $(1,563) | $5,562 | [Notes to the Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) Details accounting policies and financial items, covering business, revenue, segment performance, debt, leases, and contingencies - As of March 31, 2022, the Company's subsidiaries operated **88 home health, hospice and home care agencies** and **52 senior living communities**[21](index=21&type=chunk) Revenue by Payor - Q1 2022 vs Q1 2021 | Payor | Q1 2022 Revenue ($ thousands) | Q1 2021 Revenue ($ thousands) | | :--- | :--- | :--- | | Medicare | $55,078 | $53,739 | | Medicaid | $15,394 | $13,853 | | Managed care | $14,036 | $11,089 | | Private and other | $29,402 | $26,982 | | **Total Revenue** | **$113,910** | **$105,663** | Segment Performance - Q1 2022 vs Q1 2021 | Segment | Q1 2022 Revenue ($ thousands) | Q1 2022 Segment Adjusted EBITDAR ($ thousands) | Q1 2021 Revenue ($ thousands) | Q1 2021 Segment Adjusted EBITDAR ($ thousands) | | :--- | :--- | :--- | :--- | :--- | | Home Health and Hospice | $80,475 | $13,948 | $74,607 | $13,791 | | Senior Living Services | $33,435 | $9,432 | $31,056 | $8,834 | - The company has a **$150 million Revolving Credit Facility**, with **$58.5 million outstanding** and **$87.3 million available** as of March 31, 2022[72](index=72&type=chunk)[73](index=73&type=chunk) - One hospice provider is subject to a Medicare payment suspension, with **$4,263 thousand** recorded in accounts receivable, net, as of March 31, 2022[103](index=103&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Analyzes Q1 2022 financial performance, covering COVID-19 impacts, business trends, segment performance, and liquidity - The company continues to be impacted by COVID-19, particularly through labor challenges such as increased wage rates and staffing shortages across the healthcare industry[116](index=116&type=chunk)[117](index=117&type=chunk)[119](index=119&type=chunk) - Under the CARES Act, the company deferred approximately **$7.8 million** in employer-paid social security taxes, with **$4.1 million remaining payable** as of March 31, 2022, and **$26.5 million** of **$28.0 million** in accelerated Medicare payments recouped by CMS[125](index=125&type=chunk)[126](index=126&type=chunk) Key Performance Indicators - Q1 2022 vs Q1 2021 | Metric | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | **Home Health Services** | | | | Total home health admissions | 10,182 | 9,097 | | **Hospice Services** | | | | Total hospice admissions | 2,409 | 2,154 | | Average hospice daily census | 2,232 | 2,308 | | **Senior Living Services** | | | | Occupancy (%) | 72.6% | 72.1% | | Avg. monthly revenue per occupied unit ($) | $3,371 | $3,186 | Reconciliation to Consolidated Adjusted EBITDA | Metric | Three Months Ended March 31, 2022 ($ thousands) | Three Months Ended March 31, 2021 ($ thousands) | | :--- | :--- | :--- | | **Consolidated Net income** | $1,158 | $913 | | **Consolidated EBITDA** | $3,332 | $2,825 | | **Consolidated Adjusted EBITDA** | $6,145 | $6,296 | [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Details market risk exposure, primarily interest rate risk from the Revolving Credit Facility, and the planned LIBOR transition by June 2023 - The company is exposed to interest rate risk through its Revolving Credit Facility, which has variable interest payments based on LIBOR[195](index=195&type=chunk) - The company does not expect to transition away from the LIBOR benchmark for its Credit Facility until June 2023, when certain USD LIBOR settings are scheduled to cease[196](index=196&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) Confirms effective disclosure controls and procedures and reports no material changes to internal control over financial reporting - Based on an evaluation by management, including the CEO and CFO, the company's disclosure controls and procedures were concluded to be effective as of March 31, 2022[197](index=197&type=chunk) - There were no material changes in the company's internal control over financial reporting during the first fiscal quarter of 2022[198](index=198&type=chunk) Part II. Other Information [Legal Proceedings](index=42&type=section&id=Item%201.%20Legal%20Proceedings) Reports involvement in various claims and lawsuits from ordinary business, not expected to materially affect financial condition or operations - The company is involved in various claims and lawsuits arising in the ordinary course of business, which management does not expect to have a material adverse effect on its financial condition or operations[201](index=201&type=chunk) [Risk Factors](index=42&type=section&id=Item%201A.%20Risk%20Factors) Updates risk factors from the 2021 Annual Report, including Medicare payment suspension and expiring COVID-19 emergency waivers - A Uniform Program Integrity Contractor (UPIC) has suspended Medicare payments for one of the company's independent operating subsidiaries, totaling **$4,263 thousand** as of March 31, 2022[203](index=203&type=chunk) - The expiration of COVID-19 Emergency Waivers, particularly those related to telehealth reimbursement and facility safety requirements, could result in increased expenses and materially affect operations, revenues, and profits[205](index=205&type=chunk) [Exhibits](index=43&type=section&id=Item%206.%20Exhibits) Lists exhibits filed with Form 10-Q, including an Operations Transfer Agreement, corporate governance documents, and CEO/CFO certifications - The Exhibit Index lists key documents filed with the report, including an Operations Transfer Agreement with affiliates of Ensign, corporate governance documents, and CEO/CFO certifications pursuant to the Sarbanes-Oxley Act[207](index=207&type=chunk)